N/A N=1,674 Validation of a Screening Tool in Geriatric Oncology
Breast Cancer · Colorectal Cancer · Head and Neck Cancer
Primary: Sensitivity of the G8 Questionnaire — 76.5 % of Participants with a positive G8
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=20 Busulfan, Fludarabine, Clofarabine With Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
Acute Myeloid Leukemia · Myelodysplastic Syndrome · Chronic Myeloid Leukemia
Primary: Treatment Related Mortality — 0; 0; 0; 0 participants
N/A N=10 A Biologic Joint Replacement Strategy to Treat Patients With Severe Knee Trauma and Post-Traumatic Knee Osteoarthritis
Post-traumatic Osteoarthritis
Primary: Visual Analogue Scale Pain Score — 2.3 units on a scale
Phase 3 N=82 Management of Etonogestrel Subdermal Implant-related Bleeding
ESI-related Bleeding
Primary: Secondary Treatment — 20; 23 Participants — p=0.37
N/A N=101 Low Dose One-Day Tc99m Protocol With a High-Efficiency Cardiac Dedicated Gamma Camera For Detection of Coronary Disease
Chest Pain
Primary: Summed Rest Score (SRS) Using American Heart Association 17 Segment Polar Map Model — 2.75; 2.95 score on a scale
Phase 2 N=23 An Investigational Study of Continuous 8-Hour Intravenous Administrations of BMS-986231 in Participants With Heart Failure and Reduced Heart Function Given a Standard Dose of Loop Diuretic
Cardiac Failure · Myocardial Failure · Congestive Heart Failure
Primary: 4-hour Urinary Output Following Intravenous Administration of 40 mg Furosemide to HFrEF Participants Receiving BMS-986231 Infusion Compared to Placebo — 900.7; 1603.3…
N/A N=40 PTNS Versus Sham Efficacy in Treatment of BPS
Interstitial Cystitis Bladder Pain Syndromes
Primary: Count of Participants With Patient Global Impression of Improvement (PG-I) Score = 1 or 2 — 2; 4 Participants
Phase 1 N=38 Safety and Tolerability of a Modified Vaccinia Ankara (MVA)-Based Vaccine Modified to Express Brachyury and T-cell Costimulatory Molecules (MVA-Brachyury-TRICOM)
Lung Cancer · Breast Cancer · Prostate Cancer
Primary: Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v4.0) — 3; 14; 17 Participants
N/A N=30 Audio-Visual Relaxation Technology for Pediatric Amplified Musculoskeletal Pain Syndrome
Amplified Musculoskeletal Pain Syndrome · Reflex Sympathetic Dystrophy · Complex Regional Pain Syndromes
Primary: The Mean Change in Pain Intensity Reported on Visual Analog Scale (VAS) — -14.9; -9.6 units on a scale
Phase 3 N=13 Belatacept Therapy for the Failing Renal Allograft
Failing Renal Allograft
Primary: Number of Participants With Donor-specific Antibody Formation — 3; 4 Participants
Phase 3 N=825 Phase III Study of Liquid Formulation of ROTAVIN
Diarrhea · Diarrhea Rotavirus
Primary: Geometric Mean Concentration (GMC) of Serum Anti-rotavirus Immunoglobulin A (IgA) Antibodies 28 Days After Second Vaccination — 48.25; 35.04 U/mL
Phase 2 N=68 New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome
Cushing Syndrome · Endocrine Disease
Primary: Sensitivity of Imaging Modalities for the Detection of ACTH-secreting Non-pituitary Tumor in Patients — 96.3; 77.1; 66.7; 100 percentage of patients
Phase 3 N=1,103 Topical Vancomycin for Neurosurgery Wound Prophylaxis
Infection · Surgery · Nervous System Diseases
Primary: Any Surgical-site Infection as Evidenced by Surgeon or Attending Physician Diagnosis, or Signs and Symptoms of Infection Assessed by Phone Call Interview or at In-office…
N/A N=37 Exercise to Prevent Muscle Mass and Functional Loss in Elderly Dialysis Patients
Chronic Kidney Disease
Primary: Maximal Oxygen Uptake — 14.5; 15.1 ml/kg/min
N/A N=34 Platelet Rich Plasma vs Hyaluronic-Acid in Hip OA (Osteoarthritis)
Hip Osteoarthritis
Primary: Survivorship, as Measured by the Frequency of Patient Withdrawal of Their Treated Hip to Undergo Surgery (Total Hip Arthroplasty [THA] or Hip Resurfacing Procedure)…